Anastasia Ivanova - Publications

Affiliations: 
Biostatistics University of North Carolina, Chapel Hill, Chapel Hill, NC 
Area:
Biostatistics Biology

51 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2017 Parke T, Marchenko O, Anisimov V, Ivanova A, Jennison C, Perevozskaya I, Song G. Comparing oncology clinical programs by use of innovative designs and expected net present value optimization: Which adaptive approach leads to the best result? Journal of Biopharmaceutical Statistics. 1-20. PMID 28281911 DOI: 10.1080/10543406.2017.1289949  1
2016 Baron JA, Barry EL, Ivanova A. Calcium and Vitamin D for the Prevention of Colorectal Adenomas. The New England Journal of Medicine. 374: 791-2. PMID 26933859 DOI: 10.1056/NEJMc1514501  1
2016 Ivanova A, Wang Y, Foster MC. The rapid enrollment design for Phase I clinical trials. Statistics in Medicine. PMID 26833922 DOI: 10.1002/Sim.6886  1
2015 Weiss JM, Villaruz LC, O'Brien J, Ivanova A, Lee C, Olson JG, Pollack G, Gorman R, Socinski MA, Stinchombe TE. Results of a Phase II Trial of Carboplatin, Pemetrexed, and Bevacizumab for the Treatment of Never or Former/Light Smoking Patients With Stage IV Non-Small Cell Lung Cancer. Clinical Lung Cancer. PMID 26774201 DOI: 10.1016/J.Cllc.2015.12.006  1
2015 Baron JA, Barry EL, Mott LA, Rees JR, Sandler RS, Snover DC, Bostick RM, Ivanova A, Cole BF, Ahnen DJ, Beck GJ, Bresalier RS, Burke CA, Church TR, Cruz-Correa M, et al. A Trial of Calcium and Vitamin D for the Prevention of Colorectal Adenomas. The New England Journal of Medicine. 373: 1519-30. PMID 26465985 DOI: 10.1056/Nejmoa1500409  1
2015 Song G, Ivanova A. Enrollment and Stopping Rules for Managing Toxicity Requiring Long Follow-Up in Phase II Oncology Trials. Journal of Biopharmaceutical Statistics. 25: 1206-14. PMID 26383917 DOI: 10.1080/10543406.2015.1086779  1
2015 Ivanova A, Zhang Z, Thompson L, Yang Y, Kotz RM, Fang X. Can Sequential Parallel Comparison Design and Two-Way Enriched Design Be Useful in Medical Device Clinical Trials? Journal of Biopharmaceutical Statistics. PMID 26368863 DOI: 10.1080/10543406.2015.1092028  1
2015 Ivanova A, Paul B, Marchenko O, Song G, Patel N, Moschos SJ. Nine-Year Change in Statistical Design, Profile, and Success Rates of Phase II Oncology Trials. Journal of Biopharmaceutical Statistics. PMID 26368744 DOI: 10.1080/10543406.2015.1092030  1
2015 Shea TC, Walko C, Chung Y, Ivanova A, Sheets J, Rao K, Gabriel D, Comeau T, Wood W, Coghill J, Armistead P, Sarantopoulos S, Serody J. Phase I/II Trial of Dose-Escalated Busulfan Delivered by Prolonged Continuous Infusion in Allogeneic Transplant Patients. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 21: 2129-35. PMID 26210442 DOI: 10.1016/J.Bbmt.2015.07.016  1
2015 Keren R, Shaikh N, Pohl H, Gravens-Mueller L, Ivanova A, Zaoutis L, Patel M, deBerardinis R, Parker A, Bhatnagar S, Haralam MA, Pope M, Kearney D, Sprague B, Barrera R, et al. Risk Factors for Recurrent Urinary Tract Infection and Renal Scarring. Pediatrics. 136: e13-21. PMID 26055855 DOI: 10.1542/Peds.2015-0409  1
2015 Ivanova A, Hoberman S. Higher order response adaptive urn designs for clinical trials with highly successful treatments. Journal of the Royal Statistical Society. Series C, Applied Statistics. 64: 175-189. PMID 25641991 DOI: 10.1111/Rssc.12066  1
2015 Sanoff HK, Kim R, Ivanova A, Alistar A, McRee AJ, O'Neil BH. Everolimus and pasireotide for advanced and metastatic hepatocellular carcinoma. Investigational New Drugs. 33: 505-9. PMID 25613083 DOI: 10.1007/S10637-015-0209-7  1
2015 McRee AJ, Sanoff HK, Carlson C, Ivanova A, O'Neil BH. A phase i trial of mFOLFOX6 combined with the oral PI3K inhibitor BKM120 in patients with advanced refractory solid tumors Investigational New Drugs. 33: 1225-1231. DOI: 10.1007/s10637-015-0298-3  1
2014 Ivanova A, Rosner GL, Marchenko O, Parke T, Perevozskaya I, Wang Y. Advances in Statistical Approaches Oncology Drug Development. Therapeutic Innovation & Regulatory Science. 48: 81-89. PMID 25949927 DOI: 10.1177/2168479013501309  1
2014 Barry EL, Mott LA, Melamed ML, Rees JR, Ivanova A, Sandler RS, Ahnen DJ, Bresalier RS, Summers RW, Bostick RM, Baron JA. Calcium supplementation increases blood creatinine concentration in a randomized controlled trial. Plos One. 9: e108094. PMID 25329821 DOI: 10.1371/Journal.Pone.0108094  1
2014 Weiss JM, Villaruz LC, Socinski MA, Ivanova A, Grilley-Olson J, Dhruva N, Stinchcombe TE. A single-arm phase II trial of pazopanib in patients with advanced non-small cell lung cancer with non-squamous histology with disease progression on bevacizumab containing therapy. Lung Cancer (Amsterdam, Netherlands). 86: 288-90. PMID 25201721 DOI: 10.1016/J.Lungcan.2014.08.011  1
2014 McRee AJ, Davies JM, Sanoff HG, Goldberg RM, Bernard S, Dees EC, Keller K, Ivanova A, O'Neil BH. A phase I trial of everolimus in combination with 5-FU/LV, mFOLFOX6 and mFOLFOX6 plus panitumumab in patients with refractory solid tumors. Cancer Chemotherapy and Pharmacology. 74: 117-23. PMID 24819684 DOI: 10.1007/S00280-014-2474-0  1
2014 Carpenter MA, John A, Weir MR, Smith SR, Hunsicker L, Kasiske BL, Kusek JW, Bostom A, Ivanova A, Levey AS, Solomon S, Pesavento T, Weiner DE. BP, cardiovascular disease, and death in the Folic Acid for Vascular Outcome Reduction in Transplantation trial. Journal of the American Society of Nephrology : Jasn. 25: 1554-62. PMID 24627349 DOI: 10.1681/Asn.2013040435  1
2014 Farnan L, Ivanova A, Peddada SD. Linear mixed effects models under inequality constraints with applications. Plos One. 9: e84778. PMID 24465432 DOI: 10.1371/Journal.Pone.0084778  1
2014 Bhatnagar S, Hoberman A, Kearney DH, Shaikh N, Moxey-Mims MM, Chesney RW, Carpenter MA, Greenfield SP, Keren R, Mattoo TK, Mathews R, Gravens-Mueller L, Ivanova A. Development and impact of an intervention to boost recruitment in a multicenter pediatric randomized clinical trial. Clinical Pediatrics. 53: 151-7. PMID 24151147 DOI: 10.1177/0009922813506961  1
2013 Ivanova A, Xiao C. Dose finding when the target dose is on a plateau of a dose-response curve: comparison of fully sequential designs. Pharmaceutical Statistics. 12: 309-14. PMID 23893900 DOI: 10.1002/Pst.1585  1
2013 Raftery L, Tepper JE, Goldberg RM, Blackstock AW, Aklilu M, Bernard SA, Ivanova A, Davies JM, O'Neil BH. A two-cohort phase I study of weekly oxaliplatin and gemcitabine, then oxaliplatin, gemcitabine, and erlotinib during radiotherapy for unresectable pancreatic carcinoma. American Journal of Clinical Oncology. 36: 250-3. PMID 22547007 DOI: 10.1097/Coc.0B013E3182467F22  1
2012 Kimple RJ, Horton JK, Livasy CA, Shields JM, Lawrence JA, Chiu WM, Ivanova A, Ollila DW, Carey LA, Halle JS, Sartor CI, Dees EC. Phase I study and biomarker analysis of lapatinib and concurrent radiation for locally advanced breast cancer. The Oncologist. 17: 1496-503. PMID 23006498 DOI: 10.1634/Theoncologist.2012-0256  1
2012 Ivanova A, Xiao C, Tymofyeyev Y. Two-stage designs for Phase 2 dose-finding trials. Statistics in Medicine. 31: 2872-81. PMID 22865626 DOI: 10.1002/Sim.5365  1
2012 Xiao C, Ivanova A. Adaptive Isotonic Estimation of the Minimum Effective and Peak Doses in the Presence of Covariates. Journal of Statistical Planning and Inference. 142: 1899-1907. PMID 22711972 DOI: 10.1016/J.Jspi.2012.01.024  1
2012 Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ, Ma CX, Liu MC, Storniolo AM, Rimawi MF, Forero-Torres A, Wolff AC, Hobday TJ, Ivanova A, Chiu WK, Ferraro M, et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 2615-23. PMID 22665533 DOI: 10.1200/Jco.2010.34.5579  1
2012 Foster MC, Amin C, Voorhees PM, van Deventer HW, Richards KL, Ivanova A, Whitman J, Chiu WM, Barr ND, Shea T. A phase I dose-escalation study of clofarabine in combination with fractionated gemtuzumab ozogamicin in patients with refractory or relapsed acute myeloid leukemia. Leukemia & Lymphoma. 53: 1331-7. PMID 22149206 DOI: 10.3109/10428194.2011.647313  1
2012 Beaven AW, Shea TC, Moore DT, Feldman T, Ivanova A, Ferraro M, Ford P, Smith J, Goy A. A phase I study evaluating ibritumomab tiuxetan (Zevalin®) in combination with bortezomib (Velcade®) in relapsed/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma. Leukemia & Lymphoma. 53: 254-8. PMID 21812533 DOI: 10.3109/10428194.2011.608445  1
2011 Ivanova A, Qaqish B, Schoenfeld DA. Optimality, sample size, and power calculations for the sequential parallel comparison design. Statistics in Medicine. 30: 2793-803. PMID 21805484 DOI: 10.1002/Sim.4292  1
2011 Davies JM, Dhruva NS, Walko CM, Socinski MA, Bernard S, Hayes DN, Kim WY, Ivanova A, Keller K, Hilbun LR, Chiu M, Dees EC, Stinchcombe TE. A phase I trial of sorafenib combined with cisplatin/etoposide or carboplatin/pemetrexed in refractory solid tumor patients. Lung Cancer (Amsterdam, Netherlands). 71: 151-5. PMID 20580118 DOI: 10.1016/J.Lungcan.2010.05.022  1
2011 Sanoff HK, Davies JM, Walko C, Irvin W, Buie L, Keller K, Ivanova A, Chiu WK, O'Neil BH, Stinchcombe TE, Dees EC. A phase I evaluation of the combination of vinflunine and erlotinib in patients with refractory solid tumors. Investigational New Drugs. 29: 978-83. PMID 20387090 DOI: 10.1007/S10637-010-9427-1  1
2010 Irvin WJ, Orlowski RZ, Chiu WK, Carey LA, Collichio FA, Bernard PS, Stijleman IJ, Perou C, Ivanova A, Dees EC. Phase II study of bortezomib and pegylated liposomal doxorubicin in the treatment of metastatic breast cancer. Clinical Breast Cancer. 10: 465-70. PMID 21147690 DOI: 10.3816/Cbc.2010.N.061  1
2010 O'Neil BH, Raftery L, Calvo BF, Chakravarthy AB, Ivanova A, Myers MO, Kim HJ, Chan E, Wise PE, Caskey LS, Bernard SA, Sanoff HK, Goldberg RM, Tepper JE. A phase I study of bortezomib in combination with standard 5-fluorouracil and external-beam radiation therapy for the treatment of locally advanced or metastatic rectal cancer. Clinical Colorectal Cancer. 9: 119-25. PMID 20378507 DOI: 10.3816/Ccc.2010.N.017  1
2009 Singh SS, Mehedint DC, Ford OH, Jeyaraj DA, Pop EA, Maygarden SJ, Ivanova A, Chandrasekhar R, Wilding GE, Mohler JL. Comparison of ACINUS, caspase-3, and TUNEL as apoptotic markers in determination of tumor growth rates of clinically localized prostate cancer using image analysis. The Prostate. 69: 1603-10. PMID 19644955 DOI: 10.1002/Pros.21019  1
2008 Knovich MA, Il'yasova D, Ivanova A, Molnár I. The association between serum copper and anaemia in the adult Second National Health and Nutrition Examination Survey (NHANES II) population. The British Journal of Nutrition. 99: 1226-9. PMID 18533287 DOI: 10.1017/S0007114507864828  1
2008 Il'yasova D, Ivanova A, Morrow JD, Cesari M, Pahor M. Correlation between two markers of inflammation, serum C-reactive protein and interleukin 6, and indices of oxidative stress in patients with high risk of cardiovascular disease. Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals. 13: 41-51. PMID 17852073 DOI: 10.1080/13547500701617708  1
2008 Salama I, Ivanova A, Qaqish B. Efficient generation of constrained block allocation sequences. Statistics in Medicine. 27: 1421-8. PMID 17729381 DOI: 10.1002/Sim.3014  1
2007 Vladimirtsev VA, Nikitina RS, Renwick N, Ivanova AA, Danilova AP, Platonov FA, Krivoshapkin VG, McLean CA, Masters CL, Gajdusek DC, Goldfarb LG. Family clustering of Viliuisk encephalomyelitis in traditional and new geographic regions. Emerging Infectious Diseases. 13: 1321-6. PMID 18252102 DOI: 10.3201/Eid1309.061585  1
2007 Wlassoff WA, Albright CD, Sivashinski MS, Ivanova A, Appelbaum JG, Salganik RI. Hydrogen peroxide overproduced in breast cancer cells can serve as an anticancer prodrug generating apoptosis-stimulating hydroxyl radicals under the effect of tamoxifen-ferrocene conjugate. The Journal of Pharmacy and Pharmacology. 59: 1549-53. PMID 17976267 DOI: 10.1211/Jpp.59.11.0013  1
2007 Stinchcombe TE, Socinski MA, Walko CM, O'Neil BH, Collichio FA, Ivanova A, Mu H, Hawkins MJ, Goldberg RM, Lindley C, Dees EC. Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane) on three treatment schedules in patients with solid tumors. Cancer Chemotherapy and Pharmacology. 60: 759-66. PMID 17285317 DOI: 10.1007/S00280-007-0423-X  1
2007 Ivanova A, Flournoy N, Chung Y. Cumulative cohort design for dose-finding Journal of Statistical Planning and Inference. 137: 2316-2327. DOI: 10.1016/J.Jspi.2006.07.009  1
2007 Ivanova A, Flournoy N. Phase I Clinical Trials Statistical Advances in the Biomedical Sciences: Clinical Trials, Epidemiology, Survival Analysis, and Bioinformatics. 1-14. DOI: 10.1002/9780470181218.ch1  1
2006 Schroeder JC, Bensen JT, Su LJ, Mishel M, Ivanova A, Smith GJ, Godley PA, Fontham ET, Mohler JL. The North Carolina-Louisiana Prostate Cancer Project (PCaP): methods and design of a multidisciplinary population-based cohort study of racial differences in prostate cancer outcomes. The Prostate. 66: 1162-76. PMID 16676364 DOI: 10.1002/Pros.20449  1
2006 Carson SS, Kress JP, Rodgers JE, Vinayak A, Campbell-Bright S, Levitt J, Bourdet S, Ivanova A, Henderson AG, Pohlman A, Chang L, Rich PB, Hall J. A randomized trial of intermittent lorazepam versus propofol with daily interruption in mechanically ventilated patients. Critical Care Medicine. 34: 1326-32. PMID 16540958 DOI: 10.1097/01.CCM.0000215513.63207.7F  1
2006 Qaqish BF, Ivanova A. Multivariate logistic models Biometrika. 93: 1011-1017. DOI: 10.1093/Biomet/93.4.1011  1
2005 Konrad TR, Howard DL, Edwards LJ, Ivanova A, Carey TS. Physician-patient racial concordance, continuity of care, and patterns of care for hypertension. American Journal of Public Health. 95: 2186-90. PMID 16257949 DOI: 10.2105/Ajph.2004.046177  1
2005 Ivanova A, Qaqish BF, Schell MJ. Continuous toxicity monitoring in phase II trials in oncology. Biometrics. 61: 540-5. PMID 16011702 DOI: 10.1111/J.1541-0420.2005.00311.X  1
2004 Il'yasova D, Morrow JD, Ivanova A, Wagenknecht LE. Epidemiological marker for oxidant status: comparison of the ELISA and the gas chromatography/mass spectrometry assay for urine 2,3-dinor-5,6-dihydro-15-F2t-isoprostane. Annals of Epidemiology. 14: 793-7. PMID 15519902 DOI: 10.1016/J.Annepidem.2004.03.003  1
2003 Berger VW, Ivanova A, Knoll MD. Minimizing predictability while retaining balance through the use of less restrictive randomization procedures. Statistics in Medicine. 22: 3017-28. PMID 12973784 DOI: 10.1002/Sim.1538  1
2003 Schwartz GG, Il'yasova D, Ivanova A. Urinary cadmium, impaired fasting glucose, and diabetes in the NHANES III. Diabetes Care. 26: 468-70. PMID 12547882 DOI: 10.2337/Diacare.26.2.468  1
2001 Ivanova A, Rosenberger WF. Adaptive designs for clinical trials with highly successful treatments Drug Information Journal. 35: 1087-1093. DOI: 10.1177/009286150103500406  1
Show low-probability matches.